{"schema_version":"secwatch.filing_event.v1","accession":"0001851734-22-000740","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2022-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.518773+00:00","generated_at":"2026-06-21T00:44:58.503010+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Vistagen to acquire Pherin for ~12.4M shares, gaining full IP rights to PH94B and PH10","bullets":["Vistagen will issue ~12.4M shares of common stock and a nominal cash payment (under $50k) to acquire Pherin.","Acquisition eliminates all future royalty and milestone payment obligations related to PH94B and PH10.","Pipeline expands with three new pherine candidates: PH15 (cognition), PH80 (migraine/hot flashes), PH284 (appetite disorders).","PH94B in Phase 3 for social anxiety disorder and Phase 2 for adjustment disorder with anxiety; PH10 in development for major depressive disorder.","Closing subject to Pherin stockholder approval and other customary conditions; lock-up of 180 days for certain Pherin holders."],"urls":{"canonical":"https://secwatch.observer/filing/0001851734-22-000740","json":"https://secwatch.observer/filing/0001851734-22-000740.json","markdown":"https://secwatch.observer/filing/0001851734-22-000740.md","text":"https://secwatch.observer/filing/0001851734-22-000740.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000185173422000740/0001851734-22-000740-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000185173422000740/vtgn20221220_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T00:44:58.503010+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bda5d7f577feb3eb272baeb17db32efd59e5d787","claim":"Vistagen Therapeutics, Inc. entered into Agreement and Plan of Merger with Pherin Pharmaceuticals, Inc. and Kevin McCarthy as Stockholder Representative (effective 2022-12-20).","evidence_excerpt":"On December 20, 2022, Vistagen Therapeutics, Inc. (the “ Company ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among the Company, VTGN Merger Sub, Inc., a wholly-owned subsidiary of the Company (“ Merger Sub ”), Pherin Pharmaceuticals, Inc. (“ Pherin ”), and Kevin McCarthy in the capacity of Stockholder Representative.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411685/000185173422000740/0001851734-22-000740-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Pherin Pharmaceuticals, Inc. and Kevin McCarthy as Stockholder Representative"},{"label":"Effective","value":"2022-12-20"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}